G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Current Portion of Long-Term Debt
kr2.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Current Portion of Long-Term Debt
kr1.4B
CAGR 3-Years
34%
CAGR 5-Years
10%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Current Portion of Long-Term Debt
kr102.1m
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Current Portion of Long-Term Debt
kr33m
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
52%
MedCap AB (publ)
STO:MCAP
Current Portion of Long-Term Debt
kr51.4m
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
-8%
M
Magle Chemoswed Holding AB
STO:MAGLE
Current Portion of Long-Term Debt
kr4.3m
CAGR 3-Years
-30%
CAGR 5-Years
20%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
2.4m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Current Portion of Long-Term Debt amounts to 2.4m SEK.

What is Genovis AB's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
110%

Over the last year, the Current Portion of Long-Term Debt growth was 110%.

Back to Top